Firefly Neuroscience Inc
Firefly Neuroscience Inc is a technology company focused on IT services and consulting, primarily operating in the health care technology sector.
Business. Firefly Neuroscience Inc (AIFF.O) is a technology company operating within the IT Services & Consulting industry, primarily generating service-based revenue. The firm is headquartered in the United States and is listed on the OTC market under the ticker AIFF.O. Specific details regarding operating segments and geographic revenue mix are not disclosed in the available data.
At a glance
What drives this business
The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.
News & coverage
0Sector rotation
Developing storylines
Analysis
AI analysisOpportunity
Upcoming catalysts
Scheduled public events. Informational only — not investment advice.
- Company
- EarningsQ2 2026 earnings (expected)2026-07-28 · estimated
- Macro
- Rate decisionReserve Bank of Australia rate decision (press conf.)2026-07-08 · AU
- Rate decisionBank of Canada rate decision (press conf.)2026-07-15 · CA
- Rate decisionEuropean Central Bank rate decision (press conf.)2026-07-16 · EU
- Rate decisionBank of Japan rate decision (press conf.)2026-07-16 · JP
- Rate decisionFederal Reserve rate decision (press conf.)2026-07-29 · US
- Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
- Macro & political
- ElectionSE Swedish Election2026-09-14 · SE
- ElectionUS U.S. Midterms2026-11-03 · US
- ElectionFR French Legislative2027-06-01 · FR
Pre-earnings brief
Signals & dispatch
Composite-score breakdown
Synthesis
Firefly Neuroscience Inc (AIFF.O) is a technology company operating within the IT Services & Consulting industry, primarily generating service-based revenue. The firm is headquartered in the United States and is listed on the OTC market under the ticker AIFF.O. Specific details regarding operating segments and geographic revenue mix are not disclosed in the available data.
Firefly Neuroscience Inc has a market capitalization of $38.84 million and a price-to-book ratio of 5.09, indicating a premium valuation relative to its book value. The company's liquidity position is characterized by a current ratio of 1.43, suggesting it has sufficient short-term assets to cover its short-term liabilities. However, the company has no long-term debt and a debt-to-equity ratio of 0.0, indicating a conservative capital structure.
The company's profitability metrics are concerning, with a return on equity of -2.60 and a return on assets of -1.8977, both significantly below industry norms. Operating income and net income are negative at -$10.21 million and -$19.88 million, respectively, indicating ongoing operational losses. Gross profit of $645,000 is modest compared to the company's revenue of $1.14 million, suggesting high cost structures or low-margin operations.
Firefly Neuroscience Inc's revenue is concentrated in a single business segment, with no disclosed geographic diversification. The company's financial snapshot does not provide segment-specific revenue data, but the absence of geographic breakdown suggests potential concentration risk. The company's operating cash flow is negative at -$8.19 million, and free cash flow is -$19.84 million, indicating a significant cash outflow from operations.
The company's growth trajectory is uncertain, with no specific revenue growth projections provided in the outlook. The negative operating and free cash flows suggest the company is not generating sufficient cash to sustain operations without external financing. The company's capital expenditure of -$128,000 is minimal, indicating limited investment in long-term assets.
Risk factors for Firefly Neuroscience Inc include low liquidity and the potential for dilution, although no immediate filing-based liquidity or dilution flags were detected. The company's negative net income and operating income suggest financial instability, and the absence of long-term debt may indicate a lack of strategic leverage. The company's valuation metrics, such as the high price-to-book ratio, suggest investor optimism despite poor financial performance.
Recent events and filings do not indicate any significant changes in the company's financial or operational status. The company's financial snapshot does not provide specific details on recent events, but the absence of immediate liquidity or dilution flags suggests a stable short-term outlook.
- Firefly Neuroscience Inc has a high price-to-book ratio of 5.09, indicating a premium valuation relative to its book value.
- The company's return on equity and return on assets are negative, suggesting poor profitability and asset utilization.
- Firefly Neuroscience Inc has no long-term debt and a debt-to-equity ratio of 0.0, indicating a conservative capital structure.
- The company's operating and free cash flows are negative, indicating a significant cash outflow from operations.
- The company's liquidity position is characterized by a current ratio of 1.43, suggesting it has sufficient short-term assets to cover its short-term liabilities.
- Firefly Neuroscience Inc's revenue is concentrated in a single business segment, with no disclosed geographic diversification.
Bull / Bear case
Generated · model-assistedIn focus — financials by report
Valuation
Revenue by segment
Business relationships
Supply chain
Peer comparison
Market position
Stress test
Predictor forecast
Options
Short squeeze
Earnings-call key lines
Estimate revisions
consensus EPS · 26-week trendSell-side observations
Themes
ESG
Risk factors
- No immediate filing-based liquidity or dilution flags were detected.
Benchmarks vs cohort
Corporate actions / M&A
FX exposure
Comparable transactions
Derivatives & instruments
Derivative transactions
- Director · Deferred Stock Units → Common StockAcquired 73 892grant · 2025-10-28
- Director · Deferred Stock Units → Common StockAcquired 49 262grant · 2025-10-28
- Director · Deferred Stock Units → Common StockAcquired 49 262grant · 2025-10-28
Actions
Ask Handelsavisen
- Market data
- Market data cache
- Issuer disclosures
- Public news
- Earnings transcripts
- Consensus estimates
- ESG data
- Return On Equitynet_income / total_equity
- Price To Bookmarket_price / (adjusted_book_value / shares_outstanding_diluted)
- Dilution Ratio(shares_outstanding_diluted - shares_outstanding_basic) / shares_outstanding_basic
- Market Priceinput from market-data provider (delayed close or quote-shim mid)
- Market Capmarket_price * shares_outstanding_diluted
- Capex To Revenuecapital_expenditure / revenue
- Firefly Neuroscience Inc Market data — financials · 2026-05-27
Ownership & reference
Top holders
- Investment Managers · as of 2026-03-310,00 %$0M
- Investment Managers · as of 2026-03-310,00 %$0M
- Investment Managers · as of 2025-12-310,00 %$0M
- Investment Managers · as of 2026-03-310,00 %$0M
- Investment Managers · as of 2026-03-310,00 %$0M
- Investment Managers · as of 2026-03-310,00 %$0M
Leadership
- Jamie BenoitChairman of the Board, Chief Executive Officer
- Stanley Arthur ReesePresident, Director
Insider activity
- Director, President and COO · Common StockOther 44 872 · 2026-03-10
- Director, Chief Executive Officer · Common StockOther 65 988 · 2026-03-10
- 10% owner · Common StockSold 78 031 @ $2,07$162K · 2025-10-22
- 10% owner · Common StockSold 19 222 @ $2,40$46K · 2025-10-21
- 10% owner · Common StockSold 33 500 @ $2,46$82K · 2025-10-20
- 10% owner · Common StockSold 45 036 @ $2,55$115K · 2025-10-17
- 10% owner · Common StockSold 40 139 @ $2,65$106K · 2025-10-16
- 10% owner · Common StockSold 17 500 @ $2,74$48K · 2025-10-15
- 10% owner · Common StockSold 29 500 @ $2,74$81K · 2025-10-14
- 10% owner · Common StockSold 32 136 @ $2,65$85K · 2025-10-13
- 10% owner · Common StockSold 74 810 @ $2,70$202K · 2025-10-10
- 10% owner · Common StockSold 30 126 @ $2,94$89K · 2025-10-09
Short positioning
Geographic breakdown
Intel & risk
Evidence & claims
From filings & derived data- Total assets (YoY) (2025-12-31 vs 2024-12-31): 127.7%Derived (calculated)
- Net margin (FY 2025-12-31): -1,741.0%Derived (calculated)
- Gross margin (FY 2025-12-31): 56.5%Derived (calculated)
- Return on equity (FY 2025-12-31): -260.3%Derived (calculated)
- Return on assets (FY 2025-12-31): -189.8%Derived (calculated)
- Current ratio (FY 2025-12-31): 1.43xDerived (calculated)
- Debt-to-equity (FY 2025-12-31): 0.37xDerived (calculated)
- Cash & equivalents (YoY) (2025-12-31 vs 2023-12-31): 302.8%Derived (calculated)
- EPS (basic) (YoY) (2025-12-31 vs 2024-12-31): -23.1%Derived (calculated)
- Gross profit (YoY) (2025-12-31 vs 2024-12-31): 497.2%Derived (calculated)
- Net income (YoY) (2025-12-31 vs 2024-12-31): -90.1%Derived (calculated)
- Operating cash flow (YoY) (2025-12-31 vs 2024-12-31): -33.1%Derived (calculated)
- Operating income (YoY) (2025-12-31 vs 2024-12-31): 11.9%Derived (calculated)
- Shareholders' equity (YoY) (2025-12-31 vs 2024-12-31): 2,136.5%Derived (calculated)
- Total liabilities (YoY) (2025-12-31 vs 2024-12-31): -42.9%Derived (calculated)
- Revenue (YoY) (2025-12-31 vs 2024-12-31): 957.4%Derived (calculated)
- R&D expense (YoY) (2025-12-31 vs 2024-12-31): -24.2%Derived (calculated)
- Current assets (annual): USD 4.03MSEC XBRL filing
- Total liabilities (annual): USD 2.84MSEC XBRL filing
- Pre-tax income (annual): USD -19.88MSEC XBRL filing
- Operating income (annual): USD -8.86MSEC XBRL filing
- Shares outstanding (annual): 13.96MSEC XBRL filing
- Gross profit (annual): USD 645KSEC XBRL filing
- Revenue (annual): USD 1.14MSEC XBRL filing